Orion Corporation, Orion Pharma

🇫🇮Finland

Country: 🇫🇮Finland

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Excretion Balance and Metabolism After a Single Oral Dose of 14C-Labelled ORM-12741

Phase 1

Completed

Conditions: Healthy Male Volunteers

Interventions: Drug: ORM-12741

First Posted Date: 2009-01-06

Last Posted Date: 2009-03-16

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 6

Registration Number: NCT00817544

Locations: 🇳🇱
PRA International, AE Zuitlaren, Netherlands

Safety and Tolerability Study With Multiple Ascending Doses of ORM-12741

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ORM-12741

First Posted Date: 2008-11-18

Last Posted Date: 2009-09-24

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 51

Registration Number: NCT00792493

Locations: 🇫🇷
Forenap Pharma, Rouffach, France

Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU

Phase 1

Completed

Conditions: Pharmacokinetics
Sedation

Interventions: Drug: Dexmedetomidine

First Posted Date: 2008-09-05

Last Posted Date: 2009-04-21

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 13

Registration Number: NCT00747721

Locations: 🇫🇮
Turku University Hospital, Turku, Finland

Suitability of 11C-ORM-13070 as a PET Tracer

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 11C-ORM-13070

First Posted Date: 2008-08-15

Last Posted Date: 2009-11-25

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 18

Registration Number: NCT00735774

Locations: 🇫🇮
Turku PET centre, Turku, Finland

Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables

Phase 2

Completed

Conditions: Transient Ischemic Attack
Stroke

Interventions: Drug: Placebo
Drug: Levosimendan

First Posted Date: 2008-06-17

Last Posted Date: 2009-11-25

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 32

Registration Number: NCT00698763

Locations: 🇫🇮
Helsinki University Hospital (HUCH), Helsinki, Finland
🇫🇮
Turku University Hospital (TYKS), Turku, Finland
🇩🇪
Heidelberg University Clinic, Heidelberg, Germany

and more 4 locations

Safety and Tolerability Study With Single Ascending Doses of ORM-12741

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ORM-12741

First Posted Date: 2008-06-09

Last Posted Date: 2010-02-11

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 120

Registration Number: NCT00693316

Locations: 🇫🇷
Forenap Pharma, Rouffach, France

Pharmacokinetic Study With Repeated Doses of Stalevo

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: levodopa, carbidopa, entacapone
Drug: levodopa, carbidopa

First Posted Date: 2008-06-09

Last Posted Date: 2008-06-09

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 19

Registration Number: NCT00693862

Locations: 🇫🇮
Pharmacokinetics laboratory/Department of Pharmacology and Toxicology, Kuopio, Finland
🇫🇮
NEURO, Helsinki, Finland
🇫🇮
Turku University Hospital, Turku, Finland

Comparison of PEG Solutions With and Without Electrolytes in the Treatment of Constipation

Phase 4

Completed

Conditions: Constipation

Interventions: Drug: Polyethylene glycol 4000 with electrolytes
Drug: Polyethylene glycol 4000

First Posted Date: 2008-01-29

Last Posted Date: 2008-10-07

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 67

Registration Number: NCT00603681

Locations: 🇫🇮
Tampereen sotainvalidien Veljeskoti, Tampere, Finland
🇫🇮
Vire Koti Kaukaharju assisted-living facility, Tampere, Finland
🇫🇮
Taatala assested-living facility, Tampere, Finland

and more 7 locations

PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding

Phase 2

Terminated

Conditions: Parkinson´s Disease

Interventions: Drug: entacapone and carbidopa
Drug: Sinemet 200mg/50mg

First Posted Date: 2007-11-21

Last Posted Date: 2008-06-16

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 16

Registration Number: NCT00562198

Locations: 🇫🇮
Oulu University Hospital, Department of Neurology, Oulu, Finland
🇫🇮
Helsinki University Hospital, Department of Neurology, Helsinki, Finland
🇫🇮
CRST, Turku, Finland

and more 2 locations

Dexmedetomidine Versus Midazolam for Continuous Sedation in the Intensive Care Unit (ICU)

Phase 3

Completed

Conditions: Continuous Sedation in Initially Sedated Adults in ICU

Interventions: Drug: Dexmedetomidine
Drug: Midazolam

First Posted Date: 2007-06-01

Last Posted Date: 2012-05-07

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 501

Registration Number: NCT00481312

Locations: 🇧🇪
ULB Erasme, Route de Lennik, Brussels, Belgium
🇧🇪
UZ Brussel, Intensive Care Dept. Laarbeeklaan 101, Brussels, Belgium
🇧🇪
Universitaer Ziekenhuis Gent, Intensieve Zorgen, De Pintelaan 185, Gent, Belgium

and more 40 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy